19th week of 2021 patent applcation highlights part 26 |
Patent application number | Title | Published |
20210139500 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | 2021-05-13 |
20210139501 | MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | 2021-05-13 |
20210139502 | SOLID FORMS OF AN S1P-RECEPTOR MODULATOR | 2021-05-13 |
20210139503 | PROCESSES FOR PREPARING AN S1P-RECEPTOR MODULATOR | 2021-05-13 |
20210139504 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | 2021-05-13 |
20210139505 | PIKfyve Inhibitors | 2021-05-13 |
20210139506 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | 2021-05-13 |
20210139507 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | 2021-05-13 |
20210139508 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | 2021-05-13 |
20210139509 | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME | 2021-05-13 |
20210139510 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | 2021-05-13 |
20210139511 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | 2021-05-13 |
20210139512 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | 2021-05-13 |
20210139513 | METHOD FOR PREPARING BORATE ESTER ON BASIS OF TRICYCLOPENTADIENYL RARE EARTH METAL COMPLEX | 2021-05-13 |
20210139514 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | 2021-05-13 |
20210139515 | Preparation of Organosilicon Compound Having (Meth)acryloyloxy Group | 2021-05-13 |
20210139516 | FLOW BATTERY AND COMPONENTS THEREOF | 2021-05-13 |
20210139517 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | 2021-05-13 |
20210139518 | NOVEL POLYMORPHIC FORM OF FERRIC MALTOL | 2021-05-13 |
20210139519 | PROCESS FOR THE PRODUCTION OF CELLULOSE, LIGNOCELLULOSIC SUGARS, LIGNOSULFONATE, AND ETHANOL | 2021-05-13 |
20210139520 | SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-( -D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER | 2021-05-13 |
20210139521 | DIARYL TREHALOSE COMPOUNDS AND USES THEREOF | 2021-05-13 |
20210139522 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | 2021-05-13 |
20210139523 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | 2021-05-13 |
20210139524 | SPIROTHIETANE NUCLEOSIDES | 2021-05-13 |
20210139525 | NUCLEOTIDE PRODRUGS | 2021-05-13 |
20210139526 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | 2021-05-13 |
20210139527 | IMPROVED PROCESS FOR EXTRACTION OF CHOLESTEROL FROM FISH OIL WASTE RESIDUE | 2021-05-13 |
20210139528 | CRYSTALLINE FORMS OF OBETICHOLIC ACID | 2021-05-13 |
20210139529 | COMPOUND AND METHOD FOR THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE CONDITIONS | 2021-05-13 |
20210139530 | STEROID DERIVATIVE REGULATORS, METHOD FOR PREPARING THE SAME, AND USES THEREOF | 2021-05-13 |
20210139531 | 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | 2021-05-13 |
20210139532 | PEPTIDE SYNTHESIS METHOD | 2021-05-13 |
20210139533 | METHOD FOR THE PURIFICATION OF COLLAGEN | 2021-05-13 |
20210139534 | METHOD FOR PURIFICATION OF ALBUMIN | 2021-05-13 |
20210139535 | METHOD FOR PURIFYING ANTIBODIES | 2021-05-13 |
20210139536 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | 2021-05-13 |
20210139537 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | 2021-05-13 |
20210139538 | METHOD OF PREPARING STAPLED PEPTIDES | 2021-05-13 |
20210139539 | NEW ANTIBACTERIAL PRODUCTS | 2021-05-13 |
20210139540 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | 2021-05-13 |
20210139541 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY AND BIOORTHOGONAL FUNCTIONAL GROUP, OR SALT THEREOF | 2021-05-13 |
20210139542 | EPITOPE RESTRICTION FOR ANTIBODY SELECTION | 2021-05-13 |
20210139543 | Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines | 2021-05-13 |
20210139544 | MOSAIC HIV-1 ENVELOPES TO INDUCE ADCC RESPONSES | 2021-05-13 |
20210139545 | STREPTAVIDIN MUTEINS AND METHODS OF USING THEM | 2021-05-13 |
20210139546 | TASTE AND FLAVOR-MODIFIER PROTEINS | 2021-05-13 |
20210139547 | OPTOGENETIC INDUCTION OF NEURODEGENERATIVE DISEASE PATHOLOGIES | 2021-05-13 |
20210139548 | NPY2 RECEPTOR AGONISTS | 2021-05-13 |
20210139549 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | 2021-05-13 |
20210139550 | HINGES 1 AND/OR 4 MODIFIED DYSTROPHINS FOR DYSTROPHINOPATHY THERAPY | 2021-05-13 |
20210139551 | COMPOSITION AND METHODS FOR DISRUPTION OF BACTERIAL BIOFILMS WITHOUT ACCOMPANYING INFLAMMATION | 2021-05-13 |
20210139552 | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS | 2021-05-13 |
20210139553 | CYTOKINE-BASED BIOACTIVATABLE DRUGS AND METHODS OF USES THEREOF | 2021-05-13 |
20210139554 | INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS | 2021-05-13 |
20210139555 | ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | 2021-05-13 |
20210139556 | CHIMERIC NOTCH RECEPTORS | 2021-05-13 |
20210139557 | VCAR COMPOSITIONS AND METHODS FOR USE | 2021-05-13 |
20210139558 | PEPTIDES | 2021-05-13 |
20210139559 | PASYLATED VEGFR/PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY | 2021-05-13 |
20210139560 | IMMUNOMODULATORY FUSION PROTEINS | 2021-05-13 |
20210139561 | METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELLS BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION | 2021-05-13 |
20210139562 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE | 2021-05-13 |
20210139563 | Fusion Proteins Comprising a Cell Surface Marker Specific VHH | 2021-05-13 |
20210139564 | METHODS AND COMPOSITIONS FOR TREATING YELLOW FEVER | 2021-05-13 |
20210139565 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | 2021-05-13 |
20210139566 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | 2021-05-13 |
20210139567 | METHOD FOR DETECTING VEROTOXIN | 2021-05-13 |
20210139568 | ANTIBODY-BASED METHODS OF DETECTING AND TREATING ALZHEIMER'S DISEASE | 2021-05-13 |
20210139569 | ANTIBODY BINDING ACTIVE ALPHA-SYNUCLEIN | 2021-05-13 |
20210139570 | FILAMIN A BINDING PROTEINS AND USES THEREOF | 2021-05-13 |
20210139571 | HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE | 2021-05-13 |
20210139572 | ANTI-TAU ANTIBODIES AND METHODS OF USE | 2021-05-13 |
20210139573 | DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES | 2021-05-13 |
20210139574 | TAU-BINDING ANTIBODIES | 2021-05-13 |
20210139575 | Improved Anti-VEGFR-2 Monoclonal Antibody | 2021-05-13 |
20210139576 | TREATMENT OF OPHTHALMOLOGIC DISEASES | 2021-05-13 |
20210139577 | LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | 2021-05-13 |
20210139578 | VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF | 2021-05-13 |
20210139579 | MULTISPECIFIC ANTIBODY PRODUCT THAT BINDS TO DIFFERENT ROR1 EPITOPES | 2021-05-13 |
20210139580 | ANTI-CD33 AND ANTI-CD7 COMBINATION TREATMENT | 2021-05-13 |
20210139581 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF | 2021-05-13 |
20210139582 | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES | 2021-05-13 |
20210139583 | PRODUCTION OF ENGINEERED T-CELLS BY SLEEPING BEAUTY TRANSPOSON COUPLED WITH METHOTREXATE SELECTION | 2021-05-13 |
20210139584 | DOSING REGIMEN FOR ANTI-BCMA AGENTS | 2021-05-13 |
20210139585 | CD19 BINDING MOLECULES AND USES THEREOF | 2021-05-13 |
20210139586 | BISPECIFIC SIGNALING AGENTS AND USES THEREOF | 2021-05-13 |
20210139587 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM | 2021-05-13 |
20210139588 | ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-1 AND METHODS OF USE THEREOF | 2021-05-13 |
20210139589 | ANTI-VISTA ANTIBODIES AND METHODS OF USE | 2021-05-13 |
20210139590 | FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE | 2021-05-13 |
20210139591 | DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR | 2021-05-13 |
20210139592 | ANTI-HUMAN PD-L1 ANTIBODIES AND THEIR USES | 2021-05-13 |
20210139593 | HUMAN ANTIBODY AND FRAGMENTS THEREOF FOR USE IN THE TREATMENT OF GASTRIC CANCER (GC) AND OTHER TYPES OF TUMOURS EXPRESSING THE MICA PROTEIN (MHC CLASS I CHAIN-RELATED PROTEIN A GENE) | 2021-05-13 |
20210139594 | ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE | 2021-05-13 |
20210139595 | TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR | 2021-05-13 |
20210139596 | MODIFIED ANTIBODIES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2021-05-13 |
20210139597 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT | 2021-05-13 |
20210139598 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | 2021-05-13 |
20210139599 | RECOMBINANT IMMUNOGLOBULINS OF A NEW IGG5 CLASS, ENCODED BY THE HUMAN HEAVY CHAIN PSEUDO-GAMMA GENE | 2021-05-13 |